R-3750 in Patients With Mild to Moderate Ulcerative Colitis
Part of paid clinical trials in Valencia, California.
- Sponsor
- Rise Therapeutics LLC
- Study ID
- NCT05666960
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Ulcerative Colitis
- Ulcerative Colitis Chronic
- Ulcerative Colitis Chronic Mild
- Ulcerative Colitis Chronic Moderate
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- R-3750 — DRUGProbiotic
Study Details
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis. Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
Key Dates
- Start date
- Feb 27, 2023
- Status verified
- Jan 2026
- Primary completion
- Jul 31, 2026
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 36 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
To assess the tolerability of R-3750 [ Time Frame: 6 weeks ]
Central Contacts
- Janet Stephens, PhD6504178556
- Christian Freguia, PhD2159231818
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Amicis Research Center | Valencia | California | 91355 | Robert Moghimi, MD (PRINCIPAL_INVESTIGATOR) |
| AP Medical Research LLC | Miami | Florida | 33165 | Idania Fernandez, MD (PRINCIPAL_INVESTIGATOR) |
| Edward Jenner Research Group, LLC | Plantation | Florida | 33317 | Shadi Tarazi, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic | Rochester | Minnesota | 55902 | Darrel Pardi, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Valencia, CA
By condition
Related Studies
- Improving the Quality of Care for Adults With Inflammatory Bowel DiseaseEnrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
- The Influence of a Fasting Mimicking Diet on Ulcerative ColitisRecruiting · Stanford University · Palo Alto, California
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative ColitisPHASE4 · Recruiting · Bausch Health Americas, Inc. · Garden Grove, California